Major players in the anti-asthmatics and chronic obstructive pulmonary disease (COPD) market are Novartis AG, Merck & Co, GlaxoSmithKline , Boehringer Ingelheim Gmbh and AstraZeneca. The global anti-asthmatics and copd drugs market is expected to grow from $52 billion in 2019 to $77.
New York, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Anti-Asthmatics And COPD Drugs Global Market Report 2020-30: Covid 19 Implications and Growth" - https://www.reportlinker.com/p05967823/?utm_source=GNW
3 billion in 2020 at a compound annual growth rate (CAGR) of 48.8%. The respiratory drugs market witnessed significant growth mainly due to the COVID-19 outbreak. The fact that Covid-19 is essentially a respiratory ailment has boosted the market growth. The market is then expected to grow at a CAGR of 5.7% from 2021 and reach $83.8 billion in 2023.
The anti-asthmatics and chronic obstructive pulmonary disease (COPD) market consists of sales of anti-asthmatics and chronic obstructive pulmonary disease (COPD) drugs which are used to relieve the frequency of acute attacks of asthma, emphysema, chronic bronchitis, and nocturnal awakenings. The class of drugs includes Bronchodilators, anti-inflammatory drugs, monoclonal antibodies and combination drugs.
North America was the largest region in the anti-asthmatics and COPD drugs market in 2017.
Many inhalers that do not use chlorofluorocarbons (CFC) are already available for the treatment of asthma and chronic obstructive pulmonary disease. These products aren’t necessarily ""official"" direct alternatives to CFC Metered Dose Inhalers, but may in many patients serve as a useful medication that could replace the need for a particular CFC Metered Dose Inhaler. FDA will determine official alternatives by using the criteria established through notice-and-comment rulemaking.
The use of combination drugs for the treatment of asthma and COPD is increasing. This is due to the greater impact on patient reported outcomes (PROs) compared to monotherapies. For example, combination of short acting beta agonists (SABA) and short acting muscarinic antagnoists (SAMA) are superior compared to either medication alone in improving lung function. The use of combination long acting beta agonists (LABA), and long acting muscarnic antagonists (LAMA) have improved lung function than long acting monotherapy bronchodilators.
Increasing patent expiration of innovator drugs is restraining the anti-asthamatics and COPD drug market. Due to patent expiration, generic drugs are entering the market which are inexpensive when compared to innovator drugs. For example, patent for Advair Diskus inhaler by GSK has expired in 2016, and many players including Novartis, Hikama, and Mylan are trying to get FDA approval for a generic version of the innovator drug.
Modifiable risk factors including smoking, lack of physical exercise, and unhealthy eating habits drive the Asthma and COPD drugs market. Even though there is a decreasing trend of smoking prevalence globally, developing countries such as China, India, Indonesia, and Nigeria among others have increasing smoking prevalence. For instance, the number of tobacco smokers is set to increase by 24 million in Indonesia and by 7 million in Nigeria from 2015 to 2025, and more than 40% of global cigarette consumption is concentrated in China. Consumption of fats including saturated fatty acids which is a risk factor for Asthma and COPD is more in high income countries including USA and Europe. According to WHO, in developed countries more than 35% of total energy requirement is derived from fats when compared to <20% in low income countries, and <25% in lower middle income countries.
Read the full report: https://www.reportlinker.com/p05967823/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001